A recently completed clinical trial investigated the safety and clinical efficacy of GP2 and AE37 combined with the immunoadjuvant GM-CSF in high-risk breast cancer patients with any level of HER2 expression in adjuvant settings. Here, ERBB2 is linked to breast carcinoma.